Zurück zur Suche

Projektnummer

N000562

Zusammenfassung

Cancer continues to be one of the leading causes of death worldwide. In addition to facing unknown prospect of recovery, patients are stressed by medical treatment. Particularly, repeated painful intravenous administration of chemotherapeutics and serious side effects of the systemic therapy reduce patients' quality of life. Moreover, chemotherapy patients are often immune-compromised, hence are very vulnerable to antibiotics-resistant bacteria prevalent in hospitals. To overcome these limitations, the project aims to develop an actively-targeted anti-cancer drug delivery system for or...

Projektinformationen

Status:

Beendet

Startdatum:

01.09.2016

Enddatum:

31.08.2019

Fördersumme:

248.900 €

Profilbereich:

zukunft.niedersachsen

Förderinitiative:

Forschungskooperation Niedersachsen-Israel